Background The global prevalence of ulcerative colitis is increasing, and induction and
maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety …

Abstract Background and Aims Filgotinib is a small molecule that selectively inhibits Janus
kinase [JAK] type 1. It is already approved for the treatment of rheumatoid arthritis and is …

Summary Background Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered,
Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined the efficacy and …

Background ABX464 (obefazimod) is a small molecule that selectively upregulates miR-124
in immune cells. We aimed to assess ABX464 as a treatment for patients with moderate-to …

Background There is a growing armamentarium for the treatment of moderate-to-severe
ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small …

Background & Aims The efficacy and safety of ritlecitinib (oral JAK3/TEC family kinase
inhibitor) and brepocitinib (oral TYK2/JAK1 inhibitor) as induction therapy were assessed in …

Background Tumour necrosis factor alpha (TNF α)‐antagonism effectively treats ulcerative
colitis (UC). The golimumab clinical programme evaluated subcutaneous (SC) and …

Abstract Background and Aims Janus kinase [JAK] inhibitors have shown efficacy in
ulcerative colitis [UC]. We studied the dose-response, efficacy, and safety of peficitinib, an …

Background Despite the introduction of new monoclonal antibodies and oral therapies for
the treatment of ulcerative colitis, clinical remission rates remain low, underscoring the need …

Background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis
factor α, is an established treatment for Crohn's disease but not ulcerative colitis. Methods …